Structural O
and O
functional O
brain O
biomarkers O
of O
clinical O
response O
to O
rTMS O
of O
medication-resistant O
auditory O
hallucinations O
in O
schizophrenia O
patients O
: O
study O
protocol O
for O
a O
randomized O
sham-controlled O
double-blind O
clinical O
trial O
Background O
The O
potential O
of O
non-invasive O
repetitive O
transcranial O
magnetic O
stimulation O
( O
rTMS O
) O
to O
improve O
auditory O
verbal O
hallucinations O
( O
AVH O
) O
in O
schizophrenia O
patients O
has O
been O
increasingly O
explored O
over O
the O
past O
decade O
. O

Despite O
highly O
promising O
results O
, O
high O
inter-individual O
variability O
of O
clinical O
response O
and O
ineffective O
outcomes O
in O
a O
significant O
number O
of O
patients O
underscored O
the O
need O
to O
identify O
factors O
associated O
with O
the O
clinical O
response O
to O
rTMS O
. O

It O
should O
help O
improve O
the O
efficacy O
of O
rTMS O
in O
patients O
with O
medication-resistant O
AVH O
, O
and O
allow O
a O
better O
understanding O
of O
its O
neural O
impact O
. O

Here O
, O
we O
describe O
an O
exploratory O
study O
protocol O
which O
aims O
to O
identify O
structural O
and O
functional O
brain O
biomarkers O
associated O
with O
clinical O
response O
after O
an O
rTMS O
treatment O
for O
medication-resistant O
AVH O
in O
schizophrenia O
. O

Methods O
Forty-five O
schizophrenia O
patients O
with O
medication-resistant O
AVH O
will O
be O
enrolled O
in O
a O
double-blind O
randomized O
sham-controlled O
monocentric O
clinical O
trial O
. O

Patients O
will O
be O
assigned O
to O
a O
regime O
of O
20 O
sessions O
of O
active O
or O
sham O
1 O
Hz O
rTMS O
delivered O
twice O
a O
day O
, O
5 O
days O
a O
week O
for O
2 O
weeks O
over O
the O
left O
temporo-parietal O
junction O
. O

Response O
will O
be O
assessed O
after O
rTMS O
and O
patients O
will O
be O
classified O
in O
responders O
or O
non-responders O
to O
treatment O
. O

Magnetic O
resonance O
imaging O
( O
MRI O
) O
sessions O
including O
diffusion O
weighted O
imaging O
and O
resting-state O
functional O
MRI O
sequences O
will O
be O
recorded O
before O
the O
onset O
of O
the O
rTMS O
treatment O
and O
3 O
days O
following O
its O
discontinuation O
. O

The O
primary O
outcome O
measure O
is O
difference O
in O
fractional O
anisotropy O
between O
responder O
and O
non-responder O
patients O
at O
baseline O
. O

Differences O
in O
resting-state O
functional O
MRI O
data O
at O
baseline O
will O
be O
also O
investigated O
between O
responder O
and O
non-responder O
groups O
. O

Clinical O
, O
neuropsychological O
, O
neurophysiological O
, O
and O
blood O
serum O
BDNF O
assessments O
will O
be O
performed O
at O
baseline O
, O
3 O
days O
, O
1 O
month O
, O
and O
3 O
months O
following O
rTMS O
. O

Discussion O
The O
aim O
of O
this O
research O
project O
is O
to O
identify O
and O
assess O
the O
biomarker O
value O
of O
MRI-based O
structural O
and O
functional O
biomarkers O
predicting O
clinical O
response O
to O
rTMS O
for O
AVH O
in O
schizophrenia O
patients O
. O

The O
outcome O
of O
the O
trial O
should O
improve O
patient O
care O
by O
offering O
them O
a O
novel O
suitable O
therapy O
and O
deepen O
our O
understanding O
on O
how O
rTMS O
may O
impact O
AVH O
and O
develop O
more O
effective O
therapies O
adapted O
to O
individual O
patient O
needs O
. O

Trial O
registration O
ClinicalTrials.gov O
, O
NCT02755623 O
. O

Registered O
on O
22 O
April O
2016 O
. O

Electronic O
supplementary O
material O
The O
online O
version O
of O
this O
article O
( O
10.1186/s13063-019-3311-x O
) O
contains O
supplementary O
material O
, O
which O
is O
available O
to O
authorized O
users O
. O

Methods/design O
Study O
design O
This O
is O
a O
randomized O
, O
sham-controlled O
double-blind O
, O
monocentric O
study O
. O

Patients O
will O
be O
randomly O
assigned O
to O
one O
of O
two O
arms O
, O
either O
active O
rTMS O
or O
sham O
rTMS O
applied O
to O
the O
left O
TPJ O
of O
each O
patient O
. O

Twenty O
sessions O
of O
rTMS O
treatment O
will O
be O
administered O
daily O
( O
from O
Monday O
to O
Friday O
, O
weekends O
off O
) O
at O
a O
frequency O
of O
1 O
Hz O
for O
a O
period O
of O
2 O
weeks O
. O

Clinical O
, O
neuropsychological O
, O
neurophysiological O
, O
and O
biological O
evaluations O
will O
be O
carried O
out O
before O
regime O
onset O
( O
W0 O
) O
, O
on O
the O
week O
following O
the O
end O
of O
rTMS O
treatment O
( O
W3 O
) O
, O
and O
at O
1 O
( O
W7 O
) O
and O
3 O
months O
( O
W15 O
) O
after O
the O
termination O
of O
rTMS O
treatment O
. O

MRI O
sequences O
will O
be O
recorded O
at O
W0 O
and O
W3 O
. O

The O
first O
MRI O
acquisition O
will O
be O
recorded O
on O
the O
Friday O
of O
W0 O
( O
3 O
days O
before O
rTMS O
treatment O
) O
and O
the O
second O
on O
the O
Monday O
of O
W3 O
( O
3 O
days O
after O
rTMS O
treatment O
) O
. O

Figures O
1 O
and O
2 O
show O
the O
experimental O
design O
. O

The O
protocol O
study O
follows O
the O
SPIRIT O
recommendations O
. O

For O
the O
SPIRIT O
checklist O
see O
Additional O
file O
1 O
. O

Study O
setting O
This O
trial O
will O
be O
conducted O
by O
the O
Unité O
de O
Recherche O
Clinique O
of O
the O
Etablissement O
Public O
de O
Santé O
Ville-Evrard O
( O
Neuilly-sur-Marne O
, O
France O
) O
. O

All O
assessments O
and O
rTMS O
interventions O
will O
be O
performed O
at O
the O
Unité O
de O
Recherche O
Clinique O
of O
the O
Établissement O
Public O
de O
Santé O
Ville-Evrard O
. O

The O
MRI O
acquisitions O
will O
be O
performed O
at O
the O
Center O
for O
Neuroimaging O
Research O
at O
the O
Institut O
du O
Cerveau O
et O
de O
la O
Moelle O
Epinière O
( O
Paris O
, O
France O
) O
. O

Participants O
Recruitment O
Participants O
will O
be O
enrolled O
through O
psychiatric O
services O
of O
the O
Établissement O
Public O
de O
Santé O
Ville-Evrard O
, O
hospitals O
of O
the O
region O
Ile-de-France O
( O
within O
and O
around O
Paris O
, O
France O
) O
and O
referral O
by O
medical O
practitioners O
or O
therapists O
. O

The O
choice O
of O
rTMS O
treatment O
for O
schizophrenia O
patients O
will O
be O
decided O
by O
their O
clinician O
consultant O
. O

Following O
verification O
of O
the O
eligibility O
criteria O
by O
researchers O
, O
patients O
wishing O
to O
participate O
in O
the O
protocol O
will O
be O
included O
in O
the O
study O
. O

Inclusion O
criteria O
Patients O
will O
have O
to O
be O
diagnosed O
with O
schizophrenia O
according O
to O
DSM-5 O
( O
Diagnostic O
and O
Statistical O
Manual O
of O
Mental O
Disorders O
, O
5th O
edition O
) O
criteria O
, O
suffer O
from O
medication-resistant O
AVH O
, O
demonstrate O
clinical O
stability O
for O
at O
least O
3 O
months O
, O
be O
aged O
between O
18 O
and O
65 O
years O
old O
, O
and O
be O
right-handed O
. O

Medication O
refractoriness O
is O
defined O
as O
a O
failure O
of O
treatment O
with O
two O
different O
antipsychotic O
drugs O
, O
of O
which O
at O
least O
one O
is O
considered O
atypical O
. O

Patients O
and O
their O
physicians O
will O
be O
strongly O
instructed O
not O
to O
modify O
the O
pharmacological O
treatment O
right O
before O
or O
throughout O
participation O
in O
the O
study O
. O

Additionally O
, O
patients O
will O
have O
to O
have O
sufficient O
knowledge O
of O
the O
French O
language O
. O

All O
participants O
of O
the O
study O
will O
be O
asked O
to O
sign O
an O
informed O
consent O
form O
. O

Non-inclusion O
criteria O
Patients O
presenting O
with O
at O
least O
one O
of O
the O
following O
criteria O
are O
not O
to O
be O
enrolled O
in O
the O
study O
: O
( O
1 O
) O
major O
psychiatric O
disorders O
other O
than O
schizophrenia O
according O
to O
DSM-5 O
criteria O
; O
( O
2 O
) O
indulging O
in O
an O
addiction O
( O
alcohol O
, O
psychoactive O
substances O
) O
over O
the O
last O
12 O
months O
; O
( O
3 O
) O
having O
received O
rTMS O
treatment O
in O
the O
last O
12 O
months O
; O
( O
4 O
) O
participating O
in O
a O
concurrent O
research O
protocol O
; O
( O
5 O
) O
a O
history O
of O
seizures O
; O
( O
6 O
) O
having O
any O
contraindication O
for O
rTMS O
( O
patient O
with O
epilepsy O
, O
brain O
surgery O
and/or O
head O
trauma O
in O
the O
past O
, O
use O
of O
cardiac O
pacemaker O
, O
or O
surgical O
staples O
on O
the O
scalp O
) O
; O
( O
7 O
) O
having O
potential O
contraindications O
to O
MRI O
, O
e.g O
. O

pregnancy O
or O
lactating O
( O
a O
negative O
pregnancy O
test O
will O
be O
required O
if O
the O
patient O
is O
a O
female O
in O
reproductive O
years O
who O
does O
not O
use O
contraception O
) O
, O
use O
of O
a O
cardiac O
pacemaker O
or O
surgical O
staples O
, O
patients O
suffering O
a O
neurological O
disorder O
, O
head O
trauma O
or O
claustrophobia O
; O
( O
8 O
) O
patients O
with O
severe O
cardiovascular O
disease O
; O
( O
9 O
) O
patients O
with O
medication O
which O
could O
decrease O
the O
epileptic O
threshold O
( O
bupropion O
, O
methadone O
, O
and O
theophylline O
) O
; O
and O
( O
10 O
) O
patients O
placed O
in O
psychiatric O
care O
either O
by O
the O
state O
or O
a O
third O
party O
. O

Exit O
criteria O
Patients O
will O
be O
withdrawn O
from O
the O
trial O
if O
( O
1 O
) O
they O
simply O
wish O
to O
stop O
participation O
; O
( O
2 O
) O
they O
could O
not O
undergo O
the O
first O
MRI O
session O
; O
( O
3 O
) O
they O
did O
not O
complete O
the O
rTMS O
sessions O
; O
and O
( O
4 O
) O
if O
they O
suffered O
from O
worsening O
symptoms O
. O

Randomization O
and O
blinding O
The O
study O
plans O
to O
include O
a O
total O
of O
45 O
patients O
with O
schizophrenia O
randomized O
into O
two O
groups O
, O
namely O
an O
active O
rTMS O
group O
comprising O
35 O
patients O
( O
78 O
% O
of O
the O
total O
sample O
) O
and O
a O
sham O
rTMS O
group O
of O
10 O
patients O
( O
22 O
% O
) O
. O

We O
will O
use O
computer O
generated O
blocked-randomization O
with O
stratification O
on O
gender O
to O
get O
an O
equal O
number O
of O
males O
and O
females O
on O
each O
group O
. O

The O
randomization O
will O
be O
carried O
out O
in O
five O
blocks O
of O
nine O
participants O
. O

Each O
block O
will O
consist O
of O
seven O
patients O
in O
the O
active O
rTMS O
group O
and O
two O
patients O
in O
the O
sham O
rTMS O
group O
. O

Each O
patient O
will O
be O
randomized O
during O
the O
baseline O
period O
by O
VM O
. O

In O
order O
to O
eliminate O
measurement O
bias O
, O
no O
member O
of O
the O
trial O
will O
be O
aware O
of O
the O
group O
in O
which O
each O
patient O
is O
randomized O
to O
, O
with O
the O
exception O
of O
the O
caregiver O
performing O
the O
rTMS O
treatment O
sessions O
. O

At O
the O
end O
of O
the O
rTMS O
treatment O
( O
W3 O
) O
, O
the O
medical O
evaluator O
will O
debrief O
with O
patients O
on O
their O
participation O
in O
the O
protocol O
and O
document O
if O
they O
felt O
they O
had O
been O
assigned O
to O
and O
therefore O
received O
an O
active O
or O
sham O
rTMS O
treatment O
. O

Interventions O
Active O
rTMS O
protocol O
Sessions O
of O
rTMS O
treatment O
will O
be O
carried O
out O
with O
a O
standard O
70 O
mm O
figure-of-eight O
coil O
( O
Active O
Air O
Film O
coil O
, O
Magstim O
, O
Wales O
, O
UK O
) O
, O
attached O
to O
a O
Magstim O
Rapid2 O
Stimulator O
( O
Magstim O
, O
Wales O
, O
UK O
) O
. O

Participants O
will O
be O
randomly O
allocated O
to O
either O
the O
active O
rTMS O
( O
n O
= O
35 O
patients O
) O
or O
to O
the O
sham O
rTMS O
( O
n O
= O
10 O
) O
groups O
. O

For O
both O
groups O
, O
the O
treatment O
will O
be O
administered O
in O
two O
consecutive O
sessions O
of O
rTMS O
, O
each O
delivered O
for O
20 O
min O
and O
interleaved O
by O
a O
stimulation-free O
1 O
h O
interval O
. O

All O
patients O
will O
receive O
twice-daily O
rTMS O
sessions O
over O
a O
period O
of O
2 O
weeks O
( O
from O
Monday O
to O
Friday O
, O
weekends O
off O
) O
, O
and O
therefore O
accrue O
a O
total O
of O
20 O
rTMS O
stimulation O
sessions O
. O

The O
rTMS O
parameters O
that O
will O
be O
used O
are O
a O
frequency O
of O
1 O
Hz O
( O
1 O
pulse O
per O
second O
) O
, O
an O
intensity O
of O
100 O
% O
of O
the O
motor O
threshold O
( O
MT O
) O
, O
and O
1200 O
continuous O
pulses O
per O
session O
( O
thus O
2400 O
pulses O
per O
day O
and O
24,000 O
pulses O
in O
total O
for O
the O
whole O
treatment O
) O
. O

The O
MT O
is O
defined O
as O
the O
minimal O
TMS O
intensity O
required O
to O
elicit O
motor O
evoked O
potentials O
( O
MEPs O
) O
measured O
with O
electromyographic O
( O
EMG O
) O
surface O
electrodes O
placed O
on O
the O
first O
dorsal O
interosseous O
hand O
muscle O
, O
of O
at O
least O
50 O
μV O
peak-to-peak O
amplitude O
, O
at O
rest O
, O
in O
5 O
out O
of O
10 O
consecutive O
trials O
. O

The O
rTMS O
coil O
will O
be O
applied O
over O
the O
left O
TPJ O
, O
which O
will O
be O
targeted O
using O
established O
spatial O
coordinates O
for O
the O
Wernicke O
’ O
s O
area O
in O
the O
left O
TPJ O
( O
Montreal O
Neurological O
Institute O
( O
MNI O
) O
coordinates O
: O
x O
= O
− O
69 O
, O
y O
= O
− O
41 O
, O
z O
= O
11 O
) O
. O

This O
brain O
area O
will O
be O
labeled O
on O
a O
3D O
rendering O
of O
the O
patient O
’ O
s O
individual O
T1 O
MRI O
sequence O
on O
each O
patient O
. O

The O
TMS O
coil O
will O
be O
positioned O
tangential O
to O
the O
scalp O
location O
overlying O
the O
left O
TPJ O
using O
an O
MRI-based O
frameless O
stereotactic O
neuronavigation O
system O
( O
Brainsight O
, O
Rogue O
Research O
Inc. O
, O
Montreal O
, O
Canada O
) O
( O
Fig O
. O

3 O
) O
. O

Sham O
rTMS O
protocol O
The O
sham O
TMS O
treatment O
condition O
will O
be O
strictly O
identical O
to O
the O
active O
treatment O
condition O
thanks O
to O
the O
use O
of O
a O
sham O
TMS O
coil O
( O
Sham O
Air O
Film O
coil O
, O
Magstim O
, O
Wales O
, O
UK O
) O
. O

The O
sham O
rTMS O
coil O
is O
indistinguishable O
in O
terms O
of O
general O
appearance O
and O
shape O
from O
an O
active O
coil O
, O
and O
able O
to O
emulate O
periodic O
noise O
and O
scalp O
tactile O
sensations O
similar O
to O
those O
produced O
during O
the O
active O
TMS O
session O
for O
rTMS O
naïve O
patients O
or O
even O
experienced O
healthy O
subjects O
. O

Moreover O
, O
this O
coil O
has O
a O
magnetic O
shield O
that O
reduces O
the O
diffusion O
of O
the O
magnetic O
field O
under O
its O
surface O
, O
stimulating O
only O
scalp O
skin O
receptors O
or O
superficial O
muscles O
, O
without O
inducing O
any O
significant O
physiological O
transcranial O
effect O
on O
the O
brain O
. O

The O
two O
rTMS O
conditions O
will O
be O
performed O
in O
parallel O
in O
separate O
subsets O
of O
patients O
; O
therefore O
, O
patients O
and O
evaluators O
will O
not O
be O
able O
to O
differentiate O
between O
active O
and O
sham O
stimulation O
. O

Imaging O
acquisition O
Before O
and O
after O
the O
TMS O
therapy O
, O
MRI O
scans O
will O
be O
obtained O
in O
all O
participants O
on O
a O
3 O
Tesla O
scanner O
( O
Siemens O
Healthcare O
, O
Erlangen O
, O
Germany O
) O
. O

To O
characterize O
brain O
structure O
and O
navigate O
the O
rTMS O
coil O
location O
, O
we O
will O
record O
three-dimensional O
, O
high-resolution O
, O
isovoxel O
, O
T1-weighted O
brain O
volumes O
acquired O
with O
the O
following O
parameters O
: O
256 O
× O
240 O
× O
176 O
matrix O
size O
with O
176 O
contiguous O
slices O
, O
field O
of O
view O
( O
FOV O
) O
= O
256 O
mm O
, O
1 O
mm O
isotropic O
resolution O
, O
sagittal O
slice O
orientation O
, O
repetition O
time O
( O
TR O
) O
= O
2300 O
ms O
, O
and O
echo O
time O
( O
TE O
) O
= O
2.98 O
ms. O
To O
characterize O
the O
structural O
connectivity O
, O
diffusion-weighted O
images O
( O
DWIs O
) O
will O
be O
obtained O
using O
a O
DWI O
sequence O
( O
104 O
× O
104 O
× O
84 O
matrix O
size O
with O
60 O
contiguous O
slices O
, O
FOV O
= O
208 O
mm O
, O
2 O
mm O
isotropic O
resolution O
, O
transversal O
slice O
orientation O
, O
flip O
angle O
= O
90° O
, O
TR O
= O
3800 O
ms O
, O
TE O
= O
86 O
ms O
) O
. O

The O
encoding O
protocol O
will O
include O
64 O
different O
non-collinear O
directions O
( O
gradient O
factor O
b O
= O
1500 O
s/mm2 O
) O
and O
one O
image O
without O
diffusion O
weighting O
used O
as O
the O
reference O
volume O
( O
b O
= O
0 O
s/mm2 O
, O
b0 O
image O
) O
. O

To O
characterize O
functional O
connectivity O
( O
resting-state O
functional O
MRI O
or O
rs-fMRI O
) O
, O
we O
will O
record O
T2 O
* O
-weighted O
MRI O
sequence O
applied O
with O
an O
echo-planar O
gradient O
( O
192 O
× O
192 O
× O
162 O
matrix O
size O
with O
45 O
contiguous O
slices O
, O
FOV O
= O
192 O
mm O
, O
3 O
mm O
isotropic O
resolution O
, O
20 O
% O
interslice O
gap O
, O
transversal O
and O
coronal O
slice O
orientation O
, O
flip O
angle O
= O
80° O
, O
TR O
= O
2500 O
ms O
, O
TE O
= O
30 O
ms O
) O
when O
subjects O
are O
resting O
while O
keeping O
their O
eyes O
closed O
. O

Patients O
are O
instructed O
to O
relax O
, O
remain O
still O
, O
and O
not O
to O
fall O
asleep O
. O

After O
each O
MRI O
scan O
, O
we O
will O
also O
debrief O
with O
patients O
to O
investigate O
and O
document O
whether O
patients O
experienced O
hallucinations O
during O
the O
MRI O
sessions O
, O
and O
if O
so O
, O
in O
which O
sensory O
modalities O
and O
during O
which O
MRI O
sequences O
those O
might O
have O
occurred O
. O

Outcome O
measures O
Primary O
outcome O
measures O
Our O
primary O
aim O
is O
to O
identify O
brain O
connectivity O
differences O
between O
patients O
‘ O
responders O
’ O
and O
‘ O
non-responders O
’ O
to O
rTMS O
treatment O
. O

To O
cluster O
patients O
as O
‘ O
responders O
’ O
or O
‘ O
non-responders O
’ O
, O
the O
clinical O
response O
to O
rTMS O
will O
be O
defined O
as O
a O
decrease O
of O
50 O
% O
or O
more O
in O
the O
HCS O
from O
baseline O
( O
W0 O
) O
at O
the O
end O
of O
the O
active O
rTMS O
stimulation O
( O
W3 O
) O
. O

This O
definition O
is O
similar O
to O
that O
employed O
in O
previous O
studies O
. O

The O
HCS O
is O
described O
in O
the O
Clinical O
assessments O
section O
in O
the O
Secondary O
outcome O
measures O
paragraph O
and O
will O
allow O
analysis O
of O
the O
dataset O
in O
search O
of O
biomarkers O
associated O
with O
rTMS O
response O
, O
in O
particular O
structural O
and O
functional O
connectivity O
biomarkers O
. O

To O
identify O
structural O
connectivity O
biomarkers O
to O
rTMS O
therapeutic O
response O
, O
we O
will O
compare O
DWI O
datasets O
, O
acquired O
at O
baseline O
, O
between O
‘ O
responder O
’ O
and O
‘ O
non-responder O
’ O
patients O
to O
rTMS O
. O

More O
precisely O
, O
we O
will O
consider O
fractional O
anisotropy O
( O
FA O
) O
levels O
along O
tracts O
of O
interest O
that O
will O
be O
reconstructed O
from O
probabilistic O
tractography O
algorithms O
. O

FA O
levels O
will O
be O
obtained O
at O
several O
equidistant O
points O
along O
the O
tract O
of O
interest O
. O

This O
procedure O
will O
allow O
evaluation O
of O
the O
existence O
of O
global O
or O
focal O
( O
close O
to O
the O
stimulation O
site O
) O
white O
matter O
integrity O
alterations O
between O
‘ O
responders O
’ O
and O
‘ O
non-responders O
’ O
. O

Tracts O
of O
interest O
will O
include O
the O
fasciculi O
that O
are O
involved O
in O
the O
language O
network O
( O
connections O
between O
TPJ O
and O
Broca O
areas O
, O
so O
called O
the O
arcuate O
fasciculi O
on O
each O
hemisphere O
, O
and O
transcallosal O
connections O
between O
the O
TPJ O
or O
Broca O
areas O
) O
, O
and O
those O
that O
are O
part O
of O
the O
DMN O
( O
connections O
between O
the O
superior O
parietal O
cortex O
and O
prefrontal O
areas O
within O
each O
hemisphere O
; O
transcallosal O
connections O
between O
superior O
parietal O
cortex O
or O
prefrontal O
areas O
) O
. O

FA O
values O
along O
each O
tract O
will O
be O
obtained O
at O
baseline O
( O
W0 O
) O
and O
after O
rTMS O
treatment O
( O
W3 O
) O
for O
‘ O
responders O
’ O
and O
‘ O
non-responders O
’ O
. O

To O
identify O
functional O
connectivity O
biomarkers O
to O
rTMS O
response O
, O
we O
will O
compare O
functional O
volumes O
, O
obtained O
at O
baseline O
and O
at O
rest O
, O
between O
‘ O
responders O
’ O
and O
‘ O
non-responders O
’ O
. O

We O
will O
consider O
the O
connectivity O
strength O
between O
areas O
of O
networks O
of O
interest O
. O

Connectivity O
strength O
is O
the O
degree O
of O
dependence O
between O
the O
time O
courses O
of O
two O
areas O
( O
measured O
with O
a O
Pearson O
coefficient O
or O
using O
dynamic O
causal O
modeling O
( O
DCM O
) O
) O
. O

The O
networks O
of O
interest O
will O
include O
the O
DMN O
( O
bilateral O
anterior O
cingulate O
cortex O
, O
bilateral O
prefrontal O
areas O
, O
bilateral O
superior O
parietal O
areas O
, O
bilateral O
precuneus O
) O
and O
the O
language O
network O
( O
bilateral O
TPJ O
, O
Broca O
areas O
) O
. O

Connectivity O
strength O
between O
areas O
of O
these O
two O
networks O
will O
be O
obtained O
at O
baseline O
( O
W0 O
) O
and O
after O
rTMS O
treatment O
( O
W3 O
) O
in O
‘ O
responders O
’ O
and O
‘ O
non-responders O
’ O
. O

Secondary O
outcome O
measures O
Sociodemographic O
and O
clinical O
data O
For O
each O
participant O
, O
sociodemographic O
information O
( O
age O
, O
sex O
, O
educational O
level O
, O
marital O
status O
, O
main O
activity O
) O
and O
clinical O
data O
( O
onset O
of O
schizophrenia O
, O
number O
of O
hospitalizations O
, O
dosage O
of O
antipsychotic O
medication O
, O
drug O
consumption O
such O
as O
tobacco O
, O
alcohol O
and O
cannabis O
, O
history O
of O
neurostimulation O
treatment O
) O
will O
be O
registered O
in O
the O
patient O
’ O
s O
case O
report O
form O
( O
CRF O
) O
. O

Note O
that O
the O
pharmacological O
treatment O
is O
recorded O
at O
baseline O
for O
each O
patient O
and O
any O
change O
will O
be O
recorded O
in O
the O
patient O
’ O
s O
CRF O
by O
the O
psychiatrist O
in O
charge O
. O

The O
Edinburgh O
handedness O
inventory O
will O
be O
used O
to O
ensure O
that O
all O
patients O
are O
right-handed O
. O

Clinical O
assessments O
The O
Auditory O
Hallucinations O
Rating O
Scale O
( O
AHRS O
) O
is O
widely O
used O
to O
assess O
the O
presence O
and O
severity O
of O
AVH O
across O
seven O
items O
investigating O
frequency O
, O
level O
of O
reality O
, O
loudness O
, O
number O
of O
voices O
, O
length O
of O
the O
content O
, O
level O
of O
distraction O
, O
and O
distress O
. O

The O
HCS O
is O
linked O
to O
the O
AHRS O
and O
evaluates O
the O
percentage O
of O
AVH O
change O
. O

On O
a O
scale O
from O
0 O
to O
20 O
, O
a O
default O
score O
of O
10 O
will O
be O
attributed O
to O
a O
narrative O
description O
of O
the O
patient O
AVH O
prior O
to O
the O
rTMS O
sessions O
( O
baseline O
, O
W0 O
) O
. O

For O
the O
re-assessment O
of O
the O
AVH O
following O
rTMS O
treatment O
, O
scores O
will O
be O
evaluated O
again O
, O
and O
ascribed O
lower O
values O
( O
with O
0 O
corresponding O
to O
total O
absence O
of O
AVH O
) O
if O
AVH O
severity O
decreases O
, O
whereas O
a O
higher O
score O
will O
be O
ascribed O
if O
AVH O
severity O
is O
worse O
( O
with O
20 O
indicating O
twice O
the O
severity O
of O
AVH O
compared O
to O
baseline O
) O
. O

The O
scoring O
system O
of O
the O
HCS O
allows O
estimation O
of O
a O
percentage O
of O
AVH O
change O
after O
rTMS O
treatment O
. O

A O
score O
of O
5 O
or O
less O
ascribed O
by O
the O
medical O
evaluator O
at O
W3 O
indicates O
a O
decrease O
of O
50 O
% O
or O
more O
of O
AVH O
. O

In O
this O
case O
, O
the O
patient O
will O
be O
considered O
a O
‘ O
responder O
’ O
. O

Otherwise O
, O
the O
patient O
will O
be O
considered O
a O
‘ O
non-responder O
’ O
. O

The O
AHRS O
and O
HCS O
will O
be O
employed O
to O
assess O
the O
severity O
of O
AVH O
and O
the O
efficacy O
of O
rTMS O
therapy O
. O

AHRS O
and O
HCS O
will O
be O
recorded O
at O
each O
time O
point O
of O
this O
study O
( O
W0 O
, O
W3 O
, O
W7 O
, O
and O
W15 O
) O
. O

The O
Positive O
And O
Negative O
Syndrome O
Scale O
is O
a O
30-item O
scale O
, O
which O
is O
widely O
used O
to O
assess O
the O
overall O
disease O
severity O
of O
schizophrenia O
such O
as O
psychosis-related O
symptoms O
( O
hallucinatory O
behavior O
, O
delusions O
, O
emotional O
withdrawal O
, O
stereotyped O
thinking O
) O
and O
general O
psychopathology O
( O
including O
‘ O
poor O
attention O
’ O
, O
depression O
and O
anxiety O
) O
. O

In O
addition O
, O
the O
Psychotic O
Symptom O
Rating O
Scale O
( O
PSYRATS O
) O
, O
a O
17-item O
scale O
, O
will O
be O
employed O
to O
evaluate O
the O
psychotic O
symptoms O
( O
hallucinations O
and O
delusions O
) O
and O
the O
Scale O
for O
the O
Assessment O
of O
Negative O
Symptoms O
, O
a O
25-item O
scale O
, O
will O
be O
used O
to O
assess O
the O
negative O
symptoms O
in O
schizophrenia O
. O

Comorbid O
depressive O
symptoms O
will O
be O
investigated O
with O
the O
Beck O
Depression O
Inventory O
, O
a O
13-item O
, O
self-report O
rating O
inventory O
and O
the O
Calgary O
Depression O
Scale O
for O
Schizophrenia O
, O
a O
9-item O
structured O
interview O
scale O
. O

Finally O
, O
the O
Short O
Form O
( O
36 O
) O
Health O
Survey O
, O
a O
36-item O
scale O
, O
will O
be O
used O
to O
obtain O
a O
measure O
of O
the O
health-associated O
quality O
of O
life O
such O
as O
physical O
functioning O
, O
bodily O
pain O
, O
role O
limitations O
due O
to O
physical O
health O
problems O
, O
role O
limitations O
due O
to O
personal O
or O
emotional O
problems O
, O
emotional O
well-being O
, O
social O
functioning O
, O
energy/fatigue O
, O
and O
general O
health O
perceptions O
. O

All O
of O
the O
above O
clinical O
scales O
will O
be O
recorded O
at O
baseline O
( O
W0 O
) O
and O
at O
several O
stages O
following O
the O
end O
of O
the O
rTMS O
treatment O
( O
W3 O
, O
W7 O
, O
and O
W15 O
) O
. O

More O
precisely O
, O
clinical O
assessments O
at O
W3 O
will O
be O
mainly O
performed O
on O
Tuesday O
or O
Wednesday O
. O

It O
will O
be O
used O
to O
follow O
symptomatology O
of O
schizophrenia O
across O
this O
study O
and O
to O
investigate O
the O
impact O
of O
rTMS O
treatment O
on O
such O
symptoms O
, O
in O
particular O
AVH O
. O

Moreover O
, O
baseline O
AVH O
severity O
levels O
could O
also O
constitute O
a O
marker O
of O
the O
rTMS O
response O
in O
schizophrenia O
patients O
. O

Neuropsychological O
assessments O
A O
neuropsychological O
assessment O
evaluating O
performance O
on O
several O
cognitive O
domains O
( O
more O
specifically O
, O
executive O
function O
, O
mental O
flexibility O
, O
inhibition O
, O
verbal O
fluency O
, O
memory O
, O
and O
writing O
abilities O
) O
will O
be O
carried O
out O
on O
each O
participant O
. O

These O
data O
recorded O
at O
baseline O
( O
W0 O
) O
will O
be O
used O
to O
evaluate O
cognitive O
impairment O
and O
identify O
potential O
neuropsychological O
markers O
associated O
with O
rTMS O
response O
. O

Carried O
out O
in O
the O
post O
rTMS O
period O
, O
this O
assessment O
will O
also O
allow O
study O
of O
the O
impact O
of O
multiday O
rTMS O
regime O
on O
cognitive O
function O
. O

The O
assessment O
will O
be O
performed O
prior O
( O
W0 O
) O
and O
, O
most O
importantly O
, O
at O
several O
intervals O
following O
the O
end O
of O
the O
rTMS O
regime O
( O
W3 O
, O
W7 O
, O
and O
W15 O
) O
. O

It O
will O
include O
the O
following O
tasks O
: O
the O
Trail O
Making O
Test O
A O
and O
B O
, O
the O
Stroop O
test O
, O
the O
Hanoi O
Tower O
, O
the O
Wisconsin O
Card O
Sorting O
Test O
, O
a O
Verbal O
Fluency O
task O
, O
the O
California O
Verbal O
Learning O
test O
, O
the O
Digit O
Span O
and O
Visual O
Memory O
tests O
, O
an O
autobiographical O
memory O
task O
, O
and O
a O
dictation O
writing O
task O
. O

Neurophysiological O
assessments O
Before O
and O
after O
rTMS O
treatment O
, O
cortical O
excitability O
measures O
will O
be O
assessed O
for O
each O
patient O
using O
a O
standard O
70 O
mm O
figure-of-eight O
coil O
( O
MCF-B65 O
Butterfly O
Coil O
, O
MagVenture O
A/S O
, O
Farum O
, O
Denmark O
) O
attached O
to O
a O
MagPro O
R30 O
stimulator O
with O
MagOption O
( O
Medtronic O
A/S O
, O
Copenhagen O
, O
Denmark O
) O
. O

The O
MT O
will O
be O
assessed O
using O
the O
TMS O
Motor O
Threshold O
Assessment O
Tool O
( O
MTAT O
2.0 O
, O
http O
: O
//www.clinicalresearcher.org/software.htm O
) O
. O

Self-adhesive O
, O
solid O
gel-coated O
disposable O
Ag/AgCl O
surface O
electrodes O
placed O
on O
the O
first O
dorsal O
interosseous O
hand O
muscle O
will O
be O
employed O
to O
record O
these O
measures O
. O

Peak-to-peak O
MEP O
amplitudes O
will O
be O
recorded O
at O
120 O
% O
of O
the O
individual O
MT O
. O

Moreover O
, O
several O
neuroexcitability O
abnormalities O
have O
been O
described O
in O
schizophrenia O
patients O
, O
essentially O
in O
cortical O
inhibition O
. O

A O
deficit O
of O
intracortical O
inhibition O
( O
ICI O
) O
is O
the O
most O
robust O
finding O
in O
this O
patient O
population O
, O
whereas O
deficits O
of O
the O
cortical O
silent O
period O
( O
CSP O
) O
and O
MT O
have O
been O
reported O
inconsistently O
. O

In O
our O
protocol O
, O
the O
CSP O
, O
ICI O
, O
and O
intracortical O
facilitation O
( O
ICF O
) O
will O
also O
be O
recorded O
to O
monitor O
potential O
motor O
intracortical O
changes O
following O
the O
rTMS O
treatment O
over O
the O
left O
TPJ O
. O

To O
this O
regard O
, O
a O
recent O
clinical O
case O
reported O
indirect O
signs O
of O
clinical O
improvement O
and O
motor O
excitability O
changes O
via O
CSP O
in O
a O
pontine O
stroke O
patient O
after O
rTMS O
treatment O
delivered O
over O
the O
left O
TPJ O
to O
treat O
their O
AVH O
. O

The O
CSP O
will O
be O
evoked O
by O
applying O
TMS O
intensity O
at O
120 O
% O
of O
the O
individual O
MT O
while O
patients O
will O
perform O
a O
hand O
isometric O
contraction O
of O
approximately O
50 O
% O
of O
their O
maximum O
force O
. O

The O
duration O
of O
the O
CSP O
will O
be O
measured O
from O
the O
end O
of O
MEP O
until O
the O
re-occurrence O
of O
EMG O
activity O
. O

ICI O
and O
ICF O
will O
be O
determined O
using O
a O
paired-pulse O
paradigm O
. O

The O
conditioning O
subthreshold O
stimulus O
, O
which O
will O
be O
set O
at O
80 O
% O
of O
MT O
, O
will O
be O
preceded O
by O
a O
suprathreshold O
stimulus O
test O
at O
120 O
% O
of O
the O
MT O
. O

Interstimulus O
intervals O
will O
be O
set O
at O
2 O
and O
4 O
ms O
for O
ICI O
and O
at O
10 O
and O
15 O
ms O
for O
ICF O
. O

The O
EMG O
activity O
will O
be O
recorded O
by O
a O
computer O
using O
System O
PLUS O
EVOLUTION O
software O
( O
version O
1.04 O
, O
Micromed O
, O
Mâcon O
, O
France O
) O
. O

The O
MEPs O
amplitude O
at O
120 O
% O
of O
the O
MT O
as O
well O
as O
CSP O
, O
ICI O
, O
and O
ICF O
will O
be O
obtained O
prior O
( O
W0 O
) O
and O
following O
the O
rTMS O
treatment O
( O
W3 O
, O
W7 O
and O
W15 O
) O
and O
will O
be O
used O
to O
estimate O
individual O
levels O
of O
motor O
cortical O
excitability O
between O
‘ O
responder O
’ O
and O
‘ O
non-responder O
’ O
patients O
, O
monitoring O
potential O
changes O
of O
such O
across O
treatment O
and O
during O
follow-up O
. O

Electrophysiological O
measures O
comparing O
pre O
versus O
post O
rTMS O
between O
‘ O
responders O
’ O
and O
‘ O
non-responders O
’ O
could O
constitute O
a O
potential O
explanatory O
marker O
informing O
on O
rTMS O
mechanism O
of O
action O
. O

Biological O
measures O
from O
blood O
samples O
Brain-derived O
neurotrophic O
factor O
( O
BDNF O
) O
is O
a O
neurotrophin O
that O
plays O
a O
key O
role O
in O
neuronal O
survival O
and O
synaptic O
plasticity O
( O
i.e O
. O

morphological O
and O
physiological O
changes O
of O
synapses O
induced O
by O
neuronal O
activity O
changes O
) O
. O

BDNF O
levels O
may O
reflect O
a O
decrease O
or O
increase O
of O
brain O
activity O
and O
provide O
a O
potential O
explanatory O
marker O
of O
rTMS O
effects O
. O

Serum O
BDNF O
levels O
will O
be O
measured O
and O
compared O
between O
‘ O
responder O
’ O
versus O
‘ O
non-responder O
’ O
patient O
groups O
and O
also O
between O
active O
rTMS O
versus O
sham O
rTMS O
stimulated O
groups O
of O
patients O
. O

This O
will O
allow O
investigation O
of O
rTMS-induced O
brain O
plasticity O
changes O
. O

To O
this O
end O
, O
blood O
samples O
will O
be O
collected O
from O
all O
patients O
in O
the O
morning O
( O
before O
10:00 O
a.m. O
) O
at O
baseline O
( O
W0 O
) O
and O
after O
the O
end O
of O
the O
regime O
( O
W3 O
, O
W7 O
, O
and O
W15 O
) O
in O
a O
3.5 O
mL O
serum O
separator O
tube O
( O
SST™ O
II O
Advance O
, O
BD O
Vacutainer® O
, O
New O
Jersey O
, O
USA O
) O
. O

Blood O
samples O
will O
be O
stored O
at O
room O
temperature O
for O
20 O
min O
, O
then O
centrifuged O
at O
3500 O
rpm O
at O
4 O
°C O
for O
20 O
min O
. O

Serum O
will O
be O
separated O
from O
blood O
and O
kept O
in O
a O
refrigerator O
at O
− O
30 O
°C O
prior O
to O
analyses O
. O

Serum O
optical O
density O
will O
be O
measured O
at O
450 O
nm O
using O
a O
microplate O
reader O
( O
EZ O
Read O
400 O
, O
Biochrom O
, O
Cambridge O
, O
UK O
) O
. O

BDNF O
concentrations O
will O
be O
determined O
by O
comparing O
the O
optical O
density O
to O
a O
standard O
curve O
. O

Participant O
timeline O
The O
week O
prior O
to O
the O
onset O
of O
the O
10-day O
rTMS O
treatment O
, O
clinical O
scales O
, O
neuropsychological O
tests O
, O
structural O
and O
functional O
MRI O
recordings O
, O
neurophysiological O
motor O
excitability O
evaluations O
, O
and O
biological O
markers O
from O
blood O
serum O
samples O
will O
be O
obtained O
. O

Once O
baseline O
recordings O
are O
completed O
, O
the O
rTMS O
treatment O
will O
start O
. O

Each O
patient O
will O
receive O
a O
total O
of O
20 O
sessions O
of O
1 O
Hz O
rTMS O
( O
1200 O
pulses/session O
, O
two O
sessions/day O
from O
Monday O
to O
Friday O
, O
over O
two O
consecutive O
weeks O
) O
, O
delivered O
on O
the O
left O
TPJ O
region O
. O

Once O
the O
rTMS O
treatment O
is O
completed O
, O
many O
of O
the O
same O
clinical O
, O
neuropsychological O
, O
neuroimaging O
, O
and O
neurophysiological O
measures O
determined O
during O
the O
baseline O
prior O
to O
rTMS O
regime O
onset O
will O
be O
recorded O
again O
to O
evaluate O
the O
impact O
of O
stimulation O
( O
Fig O
. O

1 O
) O
. O

Data O
collection O
and O
management O
A O
CRF O
will O
be O
used O
to O
collect O
the O
data O
for O
each O
participant O
. O

To O
preserve O
patient O
anonymity O
, O
an O
identification O
code O
is O
allocated O
during O
the O
enrollment O
phase O
allowing O
patient O
identification O
on O
the O
CRF O
. O

Throughout O
this O
trial O
, O
CRFs O
will O
be O
reviewed O
to O
ensure O
complete O
and O
accurate O
collection O
of O
data O
following O
each O
assessment O
. O

CRFs O
will O
be O
stored O
in O
a O
locked O
cupboard O
for O
data O
security O
. O

MRI O
data O
will O
be O
stored O
on O
a O
computer O
secured O
by O
a O
password O
and O
will O
be O
identified O
with O
the O
patient O
’ O
s O
identification O
code O
to O
preserve O
anonymity O
. O

Statistical O
analysis O
Sample O
size O
The O
aim O
of O
this O
trial O
is O
to O
investigate O
the O
difference O
in O
brain O
functional O
and O
structural O
connectivity O
in O
schizophrenia O
patients O
receiving O
an O
active O
rTMS O
treatment O
and O
clinically O
responding O
to O
it O
or O
not O
as O
assessed O
by O
an O
amelioration O
of O
their O
AVH O
symptoms O
. O

Therefore O
, O
the O
sample O
size O
was O
calculated O
to O
determine O
the O
number O
of O
patients O
to O
be O
included O
in O
the O
active O
rTMS O
group O
on O
the O
basis O
of O
the O
primary O
outcome O
, O
namely O
the O
difference O
in O
FA O
values O
at O
baseline O
between O
‘ O
responders O
’ O
and O
‘ O
non-responders O
’ O
. O

Unfortunately O
, O
no O
study O
provides O
a O
significant O
difference O
of O
rs-fMRI O
measures O
or O
FA O
values O
for O
a O
given O
tract O
( O
such O
as O
the O
left O
arcuate O
fasciculus O
) O
before O
and O
following O
a O
clinically O
effective O
versus O
a O
non-clinically O
effective O
rTMS O
treatment O
in O
schizophrenia O
patients O
, O
which O
would O
allow O
us O
to O
accurately O
estimate O
the O
adequate O
sample O
size O
for O
our O
trial O
. O

Nonetheless O
, O
FA O
values O
are O
highly O
reproducible O
and O
have O
a O
reliable O
estimation O
of O
variance O
. O

Therefore O
, O
we O
focused O
on O
FA O
values O
to O
determine O
sample O
size O
. O

Therefore O
, O
on O
the O
basis O
of O
a O
significant O
difference O
in O
the O
FA O
values O
between O
schizophrenia O
patients O
and O
healthy O
subjects O
for O
the O
left O
arcuate O
fasciculus O
and O
assuming O
an O
α O
risk O
of O
0.05 O
and O
a O
1-β O
power O
of O
0.80 O
, O
we O
estimated O
the O
need O
to O
include O
32 O
patients O
for O
the O
active O
rTMS O
group O
. O

To O
overcome O
an O
estimated O
10 O
% O
drop-out O
, O
we O
increased O
our O
recruitment O
needs O
for O
active O
rTMS O
group O
to O
35 O
patients O
. O

Given O
a O
proportion O
of O
‘ O
responders O
’ O
and O
‘ O
non-responders O
’ O
to O
rTMS O
treatment O
as O
the O
one O
we O
propose O
for O
AVH O
in O
schizophrenia O
estimated O
at O
40 O
% O
and O
60 O
% O
, O
respectively O
, O
we O
will O
divide O
our O
cohort O
into O
14 O
‘ O
responders O
’ O
and O
21 O
‘ O
non-responder O
’ O
patients O
. O

According O
to O
a O
prior O
study O
, O
a O
minimum O
of O
14 O
participants O
per O
group O
( O
‘ O
responders O
’ O
or O
‘ O
non-responders O
’ O
) O
has O
been O
deemed O
sufficient O
to O
conduct O
statistical O
analysis O
in O
neuroimaging O
and O
detect O
a O
significant O
effect O
of O
rTMS O
on O
brain O
structural O
connectivity O
. O

Moreover O
, O
a O
sham O
rTMS O
group O
of O
10 O
patients O
will O
be O
followed O
in O
parallel O
to O
control O
for O
the O
placebo O
rTMS O
effect O
on O
AVH O
. O

As O
a O
result O
, O
the O
total O
number O
of O
participants O
required O
for O
the O
study O
is O
of O
45 O
patients O
. O

Data O
analysis O
In O
order O
to O
meet O
the O
objectives O
of O
this O
trial O
, O
structural O
and O
functional O
connectivity O
data O
will O
be O
processed O
in O
two O
different O
ways O
. O

First O
, O
we O
will O
compare O
measures O
, O
obtained O
at O
baseline O
( O
W0 O
) O
, O
between O
‘ O
responder O
’ O
and O
‘ O
non-responder O
’ O
patients O
submitted O
to O
active O
rTMS O
to O
identify O
potential O
brain O
biomarkers O
associated O
with O
rTMS O
response O
. O

Secondly O
, O
we O
will O
compare O
these O
same O
data O
, O
before O
versus O
after O
active O
rTMS O
, O
between O
groups O
of O
‘ O
responders O
’ O
and O
‘ O
non-responders O
’ O
to O
determine O
explanatory O
markers O
of O
active O
rTMS-induced O
AVH O
improvement O
. O

For O
both O
steps O
, O
we O
sought O
to O
show O
a O
significant O
difference O
between O
‘ O
responders O
’ O
and O
‘ O
non-responders O
’ O
. O

Thirdly O
, O
additional O
exploratory O
analysis O
will O
be O
performed O
on O
clinical O
, O
neurophysiological O
, O
neuropsychological O
, O
and O
biological O
measures O
. O

MRI O
data O
analysis O
Regions O
of O
interest O
( O
ROIs O
) O
Two O
spherical O
ROIs O
corresponding O
to O
the O
rTMS O
target O
( O
left O
TPJ O
) O
and O
its O
homotopic O
region O
in O
the O
right O
hemisphere O
( O
right O
TPJ O
) O
will O
be O
generated O
using O
the O
MarsBaR O
toolbox O
( O
http O
: O
//marsbar.sourceforge.net/ O
) O
. O

Each O
sphere O
of O
a O
5 O
mm O
radius O
will O
be O
centered O
at O
x O
= O
− O
55 O
, O
y O
= O
− O
41 O
, O
and O
y O
= O
11 O
for O
the O
left O
TPJ O
, O
and O
at O
x O
= O
55 O
, O
y O
= O
− O
41 O
, O
and O
y O
= O
11 O
for O
the O
right O
TPJ O
. O

MNI O
atlases O
will O
be O
used O
to O
define O
ROIs O
containing O
the O
nodes O
of O
the O
DMN O
and O
the O
language O
network O
. O

The O
masks O
of O
the O
left O
and O
right O
frontal O
inferior O
gyri O
and O
posterior O
cingulate O
cortex O
will O
be O
extracted O
from O
the O
WFU O
PickAtlas O
( O
http O
: O
//fmri.wfubmc.edu/software/PickAtlas O
) O
. O

A O
mask O
of O
the O
corpus O
callosum O
will O
be O
manually O
drawn O
on O
a O
T1-weighted O
MNI O
template O
using O
the O
Functional O
Magnetic O
Resonance O
Imaging O
of O
the O
Brain O
( O
FMRIB O
) O
Software O
Library O
( O
FSL O
5.0.9 O
, O
http O
: O
//www.fmrib.ox.ac.uk/fsl/ O
) O
. O

For O
tractography O
analyses O
, O
the O
same O
ROI O
will O
be O
de-normalized O
from O
the O
MNI O
space O
to O
the O
individual O
space O
using O
the O
inverse O
transformation O
obtained O
from O
the O
VBM8 O
toolbox O
. O

Structural O
connectivity O
analysis O
Diffusion O
images O
will O
be O
preprocessed O
using O
FSL O
software O
and O
then O
processed O
for O
probabilistic O
diffusion O
tractography O
with O
MRtrix3 O
software O
( O
http O
: O
//www.mrtrix.org/ O
) O
. O

Diffusion O
volumes O
will O
be O
corrected O
for O
motion O
and O
geometric O
distortions O
induced O
by O
eddy O
currents O
. O

The O
constrained O
spherical O
deconvolution O
method O
will O
be O
used O
to O
estimate O
the O
fiber O
orientation O
distribution O
function O
( O
ODF O
) O
in O
MRtrix3 O
. O

In O
the O
native O
space O
of O
each O
subject O
, O
a O
seed-to-target O
analysis O
will O
be O
performed O
to O
reconstruct O
the O
tracts O
of O
interest O
included O
in O
the O
DMN O
and O
the O
language O
network O
( O
arcuate O
fasciculus O
, O
corpus O
callosum O
) O
. O

Fiber-tracking O
maps O
will O
be O
created O
for O
each O
subject O
by O
using O
FSL O
software O
( O
data O
preprocessing O
) O
and O
MRtrix3 O
software O
( O
diffusion O
images O
) O
. O

Using O
a O
voxel-wise O
model O
of O
diffusion O
( O
the O
Q-ball O
model O
) O
, O
the O
maximum-likelihood O
solution O
for O
fiber O
orientation O
within O
each O
voxel O
will O
be O
represented O
by O
an O
ODF O
on O
the O
location O
of O
the O
fiber O
trajectory O
. O

The O
ODF O
characterizes O
the O
orientation O
dependency O
of O
the O
diffusion O
probability O
density O
function O
of O
water O
molecules O
in O
several O
possible O
directions O
for O
each O
voxel O
. O

This O
model O
can O
be O
used O
to O
track O
complex O
fiber O
configurations O
. O

The O
ODF O
information O
obtained O
from O
constrained O
spherical O
deconvolution O
will O
be O
used O
with O
a O
suitable O
fiber-tracking O
algorithm O
to O
infer O
connectivity O
of O
crossing O
fibers O
. O

We O
will O
use O
a O
probabilistic O
streamline O
algorithm O
with O
the O
entire O
ODF O
as O
a O
probability O
density O
function O
( O
ODF O
threshold O
= O
0.1 O
; O
step O
size O
= O
0.5 O
mm O
x O
voxelsize O
; O
radius O
of O
curvature O
= O
1 O
mm O
; O
up-sampling O
of O
DWIs O
, O
data O
to O
1 O
mm O
) O
. O

In O
the O
native O
individual O
space O
, O
we O
will O
perform O
a O
seed-to-target O
analysis O
from O
ROIs O
of O
the O
networks O
of O
interest O
( O
see O
Region O
of O
interest O
section O
) O
. O

These O
regions O
will O
include O
the O
bilateral O
TPJ O
, O
the O
inferior O
frontal O
gyri O
and O
the O
corpus O
callosum O
. O

We O
will O
use O
the O
following O
probabilistic O
tractography O
algorithm O
: O
the O
number O
of O
fibers O
( O
streamlines O
) O
connecting O
a O
seed O
voxel O
to O
a O
target O
voxel O
will O
be O
calculated O
by O
sampling O
1 O
million O
draws O
for O
each O
fiber O
connecting O
the O
seed O
to O
the O
target O
. O

The O
pair-wise O
connections O
of O
the O
DMN O
and O
the O
language O
networks O
will O
be O
reconstructed O
for O
each O
subject O
. O

Once O
tracts O
are O
reconstructed O
, O
one O
complementary O
measure O
will O
be O
considered O
. O

FA O
values O
will O
be O
measured O
along O
the O
tracts O
of O
interest O
. O

Along-tract O
measures O
of O
FA O
will O
be O
obtained O
on O
the O
basis O
of O
B-spline O
resampling O
of O
the O
fibers O
and O
averaging O
the O
FA O
values O
for O
each O
individual O
fiber O
on O
a O
given O
location O
( O
elastic O
model O
with O
30 O
points O
in O
space O
at O
analogous O
anatomical O
locations O
in O
each O
individual O
) O
. O

For O
instance O
, O
for O
the O
language O
network O
, O
the O
posterior O
location O
will O
be O
defined O
on O
the O
ROI O
of O
the O
TPJ O
, O
whereas O
the O
anterior O
location O
will O
be O
defined O
as O
the O
level O
of O
the O
ROI O
of O
the O
Broca O
areas O
. O

Mean O
FA O
values O
will O
be O
calculated O
at O
each O
point O
of O
the O
mean O
fiber O
along O
the O
y O
axis O
to O
check O
for O
local O
differences O
at O
specific O
points O
of O
the O
tract O
. O

A O
linear O
mixed-effects O
model O
will O
be O
applied O
serially O
for O
each O
tract O
and O
permutation O
methods O
will O
be O
performed O
to O
adjust O
the O
p O
values O
and O
control O
the O
Type O
1 O
error O
. O

Resting-state O
functional O
connectivity O
analysis O
Statistical O
parametric O
mapping O
software O
( O
SPM8 O
, O
Wellcome O
Department O
of O
Cognitive O
Neurology O
, O
London O
, O
UK O
) O
will O
be O
used O
for O
image O
processing O
( O
http O
: O
//www.fil.ion.ucl.ac.uk/spm/ O
) O
. O

The O
functional O
images O
will O
be O
interpolated O
in O
time O
to O
correct O
for O
phase O
advance O
during O
volume O
acquisition O
, O
and O
will O
be O
realigned O
with O
the O
first O
image O
of O
each O
session O
. O

The O
anatomical O
image O
and O
the O
realigned O
functional O
images O
of O
each O
subject O
will O
then O
be O
normalized O
to O
a O
common O
standard O
space O
by O
using O
the O
MNI O
template O
( O
DARTEL O
) O
. O

The O
functional O
data O
will O
be O
spatially O
smoothed O
with O
a O
4-mm O
full-width O
at O
half-maximum O
Gaussian O
filter O
and O
temporally O
filtered O
( O
0.01–0.08 O
Hz O
) O
with O
a O
128-s O
period O
high-pass O
filter O
. O

Functional O
connectivity O
analysis O
will O
be O
performed O
. O

The O
correlations O
in O
spontaneous O
BOLD O
fluctuations O
reflect O
the O
inter-regional O
correlations O
in O
neuronal O
variability O
. O

The O
averaged O
time O
course O
will O
be O
obtained O
from O
a O
previously O
defined O
ROI O
( O
posterior O
cingulate O
cortex O
for O
the O
DMN O
, O
TPJ O
for O
the O
language O
network O
) O
. O

The O
correlation O
analysis O
will O
be O
performed O
in O
a O
voxel-wise O
way O
to O
generate O
the O
functional O
connectivity O
map O
. O

The O
correlation O
coefficient O
map O
will O
be O
converted O
into O
a O
z O
map O
by O
Fisher O
’ O
s O
r-to-z O
transform O
to O
improve O
the O
normality O
( O
Data O
Processing O
Assistant O
for O
Resting-State O
fMRI O
, O
http O
: O
//www.restfmri.net O
) O
. O

For O
each O
network O
of O
interest O
( O
DMN O
, O
language O
network O
) O
, O
the O
second O
level O
analysis O
will O
be O
performed O
using O
a O
two-tailed O
, O
two-sample O
t O
test O
on O
the O
z-score O
maps O
to O
show O
group O
differences O
on O
connections O
of O
the O
DMN O
and O
language O
networks O
. O

Effective O
connectivity O
analysis O
will O
be O
performed O
using O
DCM O
with O
the O
DCM10 O
routine O
implemented O
in O
Statistical O
Parametric O
Mapping O
software O
12 O
. O

The O
first O
eigenvectors O
will O
be O
extracted O
from O
the O
ROIs O
representing O
the O
DMN O
and O
language O
networks O
( O
see O
‘ O
Regions O
of O
interest O
’ O
section O
) O
. O

The O
a O
priori O
models O
will O
be O
based O
on O
anatomical O
connections O
, O
considering O
a O
fully O
connected O
model O
of O
the O
DMN O
and O
language O
network O
. O

Intrinsic O
connectivity O
will O
be O
defined O
as O
the O
endogenous O
connectivity O
parameter O
without O
driving O
input O
. O

The O
intrinsic O
connectivity O
values O
will O
be O
obtained O
for O
each O
subject O
in O
the O
best O
model O
of O
each O
network O
that O
will O
be O
considered O
for O
group O
analysis O
. O

Bayesian O
model O
selection O
will O
be O
used O
to O
determine O
the O
best O
model O
between O
unilateral O
and O
bilateral O
connections O
. O

Expected O
posterior O
model O
probabilities O
and O
exceedance O
probabilities O
will O
be O
computed O
. O

The O
group O
analysis O
on O
the O
DCM O
parameters O
will O
only O
include O
the O
model O
that O
will O
best O
fit O
the O
data O
. O

Within O
each O
group O
, O
one O
sample O
t O
test O
will O
be O
conducted O
to O
examine O
whether O
the O
parameters O
of O
the O
model O
that O
best O
fits O
the O
data O
will O
have O
significant O
non-zero O
values O
. O

Two-sample O
t O
tests O
will O
be O
used O
to O
identify O
group O
differences O
in O
intrinsic O
connectivity O
on O
each O
connection O
. O

The O
same O
will O
be O
performed O
for O
the O
DMN O
to O
examine O
whether O
rTMS O
has O
a O
specific O
effect O
on O
the O
language O
network O
or O
a O
more O
global O
effect O
on O
attentional O
mechanisms O
. O

Demographic O
, O
clinical O
, O
neurophysiological O
, O
neuropsychological O
and O
biological O
data O
analysis O
Socio-demographic O
data O
will O
be O
compared O
between O
the O
active O
rTMS O
and O
the O
sham O
rTMS O
groups O
, O
and O
also O
between O
the O
‘ O
responder O
’ O
and O
‘ O
non-responder O
’ O
groups O
, O
using O
a O
two-sample O
t O
test O
( O
Student O
’ O
s O
t O
test O
) O
or O
a O
χ2 O
test O
. O

To O
control O
for O
the O
rTMS O
treatment O
efficacy O
, O
a O
repeated-measures O
analysis O
of O
variance O
( O
ANOVA O
) O
will O
be O
performed O
on O
AHRS O
with O
time O
( O
before/after O
rTMS O
) O
as O
the O
within-subject O
factor O
and O
group O
( O
active O
rTMS/sham O
rTMS O
) O
as O
the O
between-group O
factor O
( O
based O
on O
the O
per-protocol O
principles O
) O
. O

The O
same O
strategy O
will O
be O
followed O
for O
clinical O
, O
neurophysiological O
, O
neuropsychological O
, O
and O
biological O
data O
. O

Post-hoc O
pair-wise O
comparisons O
will O
be O
performed O
using O
a O
two-sample O
t O
test O
( O
Student O
’ O
s O
t O
test O
) O
or O
χ2 O
test O
. O

Bonferroni O
correction O
will O
be O
applied O
as O
a O
multiple O
comparison O
adjustment O
to O
reduce O
the O
chances O
of O
a O
false O
positive O
result O
. O

Normality O
of O
data O
distribution O
( O
Shapiro–Wilk O
’ O
s O
test O
) O
and O
equality O
of O
variances O
( O
Levene O
’ O
s O
test O
) O
will O
be O
previously O
verified O
. O

All O
data O
will O
be O
presented O
as O
mean O
± O
standard O
deviation O
. O

For O
all O
tests O
, O
statistical O
significance O
will O
be O
set O
as O
p O
≤ O
0.05 O
. O

